Strengthening Post-market Surveillance and Risk Management of Medical Devices in CanadaPublished on August 20, 2018
Author: Bhavesh Patel, C. Chem.
Health Canada recently informed stakeholders, in particular manufacturers and importers of medical devices, of its intent to propose regulatory changes to strengthen post-market surveillance and risk management of medical devices in Canada. The proposed regulatory reforms will involve amendments to the Medical Devices Regulations.
Health Canada has cited several reasons for the proposed changes:
- an increase in the complexity of medical devices;
- an increase in the generation and use of real-world data and evidence amongst international regulators;
- a push for greater alignment of regulations with those of other countries; and
- a need for an environment that supports the integration of new technologies into the health care system while maintaining patient safety.
To review the proposed changes in full, please follow the link in the reference section below.
Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.
Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada
What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...
Health Canada changes filing requirements for product monographs
Did you know, effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs? This is for only post-life...
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...